Pulmonx Corporation — Third Quarter 2026 Earnings Summary

Pulmonx Corporation reported third-quarter 2026 worldwide revenue of $22.8 million, reflecting a 6% year-over-year increase on both GAAP and constant currency bases. The company achieved a gross margin of 76% and reduced its net loss to $8.4 million, a 40% decrease compared to the same period in 2025. Adjusted EBITDA loss narrowed by 57% to $3.5 million, driven by an 18% reduction in operating expenses to $24.9 million. For the full year 2026, Pulmonx maintains a revenue guidance range of $90 million to $92 million and expects total operating expenses to fall between $108 million and $109 million.